Key Takeaways:
Medical marijuana's move to Schedule III freed cannabis companies from Section 280E tax penalties but created new compliance burdens — and left the far larger recreational market untouched.
President Donald Trump's executive order directing the Drug Enforcement Administration to reschedule medical marijuana from Schedule I to Schedule III, enacted in April by acting Attorney General Todd Blanche, freed cannabis companies from Internal Revenue Service Section 280E restrictions that barred Schedule I drug purveyors from deducting ordinary business expenses. The change, however, excluded recreational cannabis, which remains classified as a Schedule I substance alongside heroin and LSD.
"The escape from Section 280E is a meaningful tax advantage for medical cannabis operators, but the new compliance and record-keeping requirements for companies selling both medical and recreational products will offset some of those gains," said Eric Volkman, a cannabis industry analyst at Motley Fool. "It's a small win that brings a host of new headaches."
The policy shift affects three prominent cannabis companies differently. Canopy Growth generated more than CA$25 million ($17.7 million) in Canadian medical sales in its most recent quarter, representing nearly half of its total marijuana revenue. Tilray reported international medical sales of more than $24 million in its fiscal third quarter of 2026, up 73 percent year over year. Green Thumb Industries, a U.S. multi-state operator, does not break down its cannabis revenue between medical and recreational categories, making the financial impact difficult to quantify.
Neither Canopy Growth nor Tilray can directly export medical marijuana to the U.S., limiting the direct benefit of the rescheduling. Canopy Growth's affiliate, Canopy USA, sells medical pot in the U.S., but the parent company has elected not to consolidate Canopy USA's financials following pushback from Nasdaq. Tilray's U.S. operations focus on craft beer, not cannabis. Green Thumb holds retail licenses in states that have legalized both medical and recreational sales but has not disclosed how the rescheduling affects its tax position.
Compliance Costs Offset Tax Relief
The shift to Schedule III imposes new regulatory obligations on medical cannabis sellers, including enhanced reporting, record-keeping, and separate tracking of medical versus recreational sales. Companies operating in both segments now face the administrative burden of maintaining distinct revenue streams for tax and compliance purposes. The DEA was about to close its administrative hearing on the proposed rescheduling of non-medical marijuana as of this writing, with a decision expected to face legal challenges from both pro- and anti-reform lobbyists regardless of the outcome.
The current average U.S. tariff on Chinese goods stands at roughly 19 percent after the previous escalation rounds, according to Census Bureau data. The last time the DEA undertook a significant scheduling review — the 2020 consideration of marijuana rescheduling under the Obama-era framework — the process took more than two years and resulted in no change. Market participants expect a similarly protracted timeline for recreational rescheduling, with OIS markets pricing a low probability of completion before 2028.
Forward Outlook
Given public sentiment and the political calculus around cannabis reform, recreational rescheduling appears likely over the long term, but the timeline remains uncertain. For now, the Section 280E relief provides a modest tailwind for medical-focused operators, while the compliance burden and continued Schedule I classification for recreational products limit the scope of the policy's market impact. Canopy Growth, Tilray, and Green Thumb each face distinct challenges that the rescheduling does not materially resolve.
This article is for informational purposes only and does not constitute investment advice.
